Literature DB >> 19411097

Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan.

Angelo Maggioni1, Giovanni Roviglione, Fabio Landoni, Vanna Zanagnolo, Michele Peiretti, Nicoletta Colombo, Luca Bocciolone, Roberto Biffi, Lucas Minig, C Paul Morrow.   

Abstract

OBJECTIVES: Analyze morbidity and survival after pelvic exenteration (PE) of gynecological malignancies.
METHODS: We reviewed 106 consecutive patients with gynecologic malignancies who underwent PE from June 1996 to April 2007 at the Division of Gynecology, European Institute of Oncology (IEO), Milan.
RESULTS: PE was performed for cancer of the cervix (62 patients), vagina (21 patients), vulva (9 patients), endometrium (9 patients), ovary (4 patients) and 1 uterine sarcoma. Mean age was 53.6 (30-78) years. 97% of the patients received radiotherapy before PE and 3 patients had PE as primary treatment. We performed 53 anterior, 48 total and 5 posterior PE. Median operation time, estimated blood loss and hospital stay were respectively 490 (200-780) minutes, 1240 (300-6500) ml and 21.6 (11-55) days. No residual tumor was left in 93% of the patients. Median follow-up was 22.3 (1.6-117) months. There were no post-operative deaths (<30 days from surgery) nor intra-operative mortality. Total morbidity rate was 66%; 48% of patients had early complications (<30 days after PE) whereas 52 patients (48.5%) had late complications; 70% of these occurred to the urinary tract and 25% were due to bowel occlusions or fistulas. Overall survival was 52%, 35%, 19% and 16% respectively for cervical, endometrial, vaginal and vulvar cancer.
CONCLUSIONS: PE is a feasible technique with no post-operative mortality and high percentage of long-survivors, although the morbidity rate still remains significantly high. Careful patient selection, pre- and post-operative care and optimal surgical skills in a Gynecologic Oncologic Center are the cornerstones to further improve quality of life and survival for these patients.

Entities:  

Mesh:

Year:  2009        PMID: 19411097     DOI: 10.1016/j.ygyno.2009.03.029

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  31 in total

1.  Morbidity and outcome of pelvic exenteration in locally advanced pelvic malignancies.

Authors:  Rajaraman Ramamurthy; Amudhan Duraipandian
Journal:  Indian J Surg Oncol       Date:  2012-07-18

2.  Pelvic Exenteration Put into Therapeutical and Palliative Perspective: It Is Worth to Try.

Authors:  Iosifina Karmaniolou; Nikolaos Arkadopoulos; Pantelis Vassiliou; Constantinos Nastos; Dionysios Dellaportas; Argyris Siatelis; Theodosis Theodosopoulos; Antonios Vezakis; Stavros Parasyris; Andreas Polydorou; Vassilios Smyrniotis
Journal:  Indian J Surg Oncol       Date:  2018-07-20

Review 3.  "Unresectable" vulval cancers: is neoadjuvant chemotherapy the way forward?

Authors:  Kathryn Graham; Kevin Burton
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

4.  Outcomes of a bladder preservation technique in female patients undergoing pelvic exenteration surgery for advanced gynaecological tumours.

Authors:  Bernhard Liedl; Wael Y Khoder; Brigitte Ruhdorfer-Metz; Christian G Stief; Raphaela Waidelich
Journal:  Int Urogynecol J       Date:  2014-03-15       Impact factor: 2.894

5.  The effect of body mass index on surgical outcomes and survival following pelvic exenteration.

Authors:  David A Iglesias; Shannon N Westin; Vijayashri Rallapalli; Marilyn Huang; Bryan Fellman; Diana Urbauer; Michael Frumovitz; Pedro T Ramirez; Pamela T Soliman
Journal:  Gynecol Oncol       Date:  2012-01-16       Impact factor: 5.482

Review 6.  Contemporary quality of life issues affecting gynecologic cancer survivors.

Authors:  Jeanne Carter; Richard Penson; Richard Barakat; Lari Wenzel
Journal:  Hematol Oncol Clin North Am       Date:  2011-12-16       Impact factor: 3.722

7.  Pelvic exenteration in gynecologic oncology: a single institution study over 20 years.

Authors:  T Benn; R A Brooks; Q Zhang; M A Powell; P H Thaker; D G Mutch; I Zighelboim
Journal:  Gynecol Oncol       Date:  2011-03-27       Impact factor: 5.482

8.  Hospital surgical volume and perioperative mortality of pelvic exenteration for gynecologic malignancies.

Authors:  Koji Matsuo; Shinya Matsuzaki; Rachel S Mandelbaum; Kazuhide Matsushima; Maximilian Klar; Brendan H Grubbs; Lynda D Roman; Jason D Wright
Journal:  J Surg Oncol       Date:  2019-11-19       Impact factor: 3.454

9.  Factors affecting hospital length of stay following pelvic exenteration surgery.

Authors:  Ying Guo; Eugene Chang; Mehtap Bozkurt; Minjeong Park; Diane Liu; Jack B Fu
Journal:  J Surg Oncol       Date:  2017-10-16       Impact factor: 3.454

10.  Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer.

Authors:  Sota Tanaka; Satoru Nagase; Michiko Kaiho-Sakuma; Tomoyuki Nagai; Hiroki Kurosawa; Masafumi Toyoshima; Hideki Tokunaga; Takeo Otsuki; Hiroki Utsunomiya; Tadao Takano; Hitoshi Niikura; Kiyoshi Ito; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2013-02-13       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.